Molecular Partners AG (XSWX:MOLN) Common Stock : CHF3.64 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG Common Stock?

Molecular Partners AG's quarterly common stock increased from Sep. 2023 (CHF3.63 Mil) to Dec. 2023 (CHF3.64 Mil) and increased from Dec. 2023 (CHF3.64 Mil) to Mar. 2024 (CHF3.64 Mil).

Molecular Partners AG's annual common stock increased from Dec. 2021 (CHF3.23 Mil) to Dec. 2022 (CHF3.60 Mil) and increased from Dec. 2022 (CHF3.60 Mil) to Dec. 2023 (CHF3.64 Mil).

Molecular Partners AG Common Stock Historical Data

The historical data trend for Molecular Partners AG's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Partners AG Common Stock Chart

Molecular Partners AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

2.16

2.92

3.23

3.60

3.64

Molecular Partners AG Quarterly Data
	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Common Stock	Get a 7-Day Free Trial															3.61	3.63	3.63	3.64	3.64

Molecular Partners AG Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Molecular Partners AG (XSWX:MOLN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

MOLN:USA MLLCF:USA MOLNz:UK 6ML0:Germany

Address

Wagistrasse 14, Schlieren, Zurich, CHE, 8952

Website

https://www.molecularpartners.com

Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.